Klavant
Klavant is a MedTech company focused on revolutionizing cardiac surgery with AI-powered tools that enhance precision and decision-making. Their mission is to develop digital intraoperative quality control systems and AI-based image-assisting solutions to improve surgical outcomes and healthcare worldwide. They aim to provide surgeons with advanced measurement, visualization, and data-driven support to reduce surgery times, reoperations, costs, and lifelong medication for patients.
Industries
Nr. of Employees
small (1-50)
Products
AI-powered intraoperative quality control system for aortic valve surgery
A pre-clinical system combining imaging, AI analysis and quantitative measurement to assess aortic valve competence and support intraoperative decisions during valve repair and ascending aorta procedures.
AI-powered intraoperative quality control system for aortic valve surgery
A pre-clinical system combining imaging, AI analysis and quantitative measurement to assess aortic valve competence and support intraoperative decisions during valve repair and ascending aorta procedures.
Services
Collaborative engagement with hospitals and surgeons to evaluate pre-clinical systems, exchange abstracts and plan clinical evaluation.
Development and integration of AI-based image analysis and visualization software for surgical workflows and intraoperative quality control.
Collaborative engagement with hospitals and surgeons to evaluate pre-clinical systems, exchange abstracts and plan clinical evaluation.
Development and integration of AI-based image analysis and visualization software for surgical workflows and intraoperative quality control.
Expertise Areas
- AI for surgical decision support
- Intraoperative imaging and visualization
- Aortic valve function assessment
- Pre-clinical medical device development
Key Technologies
- AI-driven image analysis
- Real-time intraoperative imaging
- Intraoperative decision-support algorithms
- Quantitative valve-function measurement
News & Updates
Klavant has been selected to participate in the prestigious Creative Destruction Lab (CDL) Berlin program, supporting early-stage start-ups in healthcare innovation.
Klavant GmbH received a grant award of EUR 1.5 million under the 'KMU innovativ Medizintechnik' R&D funding program of the German Federal Ministry of Education and Research (BMBF).
Klavant was awarded winner of the ideas phase in the Life Science Venture Cup category among around 60 participants.
Klavant won the German medical technology business plan competition 2020 among approx. 50 applicants and 11 finalists.
Klavant won 2nd place at the hybrid startup pitching competition VENTURE.Med 2020 organized by Business Angel Network Germany.
Awarded in the highly renowned Germany-wide Science4Life competition, among around 60 participants.
Klavant has been selected to participate in the prestigious Creative Destruction Lab (CDL) Berlin program, supporting early-stage start-ups in healthcare innovation.
Klavant GmbH received a grant award of EUR 1.5 million under the 'KMU innovativ Medizintechnik' R&D funding program of the German Federal Ministry of Education and Research (BMBF).
Klavant was awarded winner of the ideas phase in the Life Science Venture Cup category among around 60 participants.
Klavant won the German medical technology business plan competition 2020 among approx. 50 applicants and 11 finalists.
Klavant won 2nd place at the hybrid startup pitching competition VENTURE.Med 2020 organized by Business Angel Network Germany.
Awarded in the highly renowned Germany-wide Science4Life competition, among around 60 participants.